Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

2
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
2
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

469
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
469
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

617
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
617
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

263
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
263
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

758
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
758

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variance-Consistent Covariate Modeling from Posterior Summaries in Population Pharmacokinetics.

Pharmaceutical research·2026
Same author

Predicting plasma concentration-time profiles of orally disintegrating tablets with delayed absorption under fed conditions without water.

International journal of pharmaceutics·2026
Same author

Platform design of hybrid microphysiological system integrating in vitro and in silico models for reproducing insulin-regulated glucose metabolism.

Scientific reports·2026
Same author

Enhancing Antigen Recognition of Living Cells by Site-Specific VHH Antibody Conjugation.

Chembiochem : a European journal of chemical biology·2025
Same author

Harnessing large language models for structured extraction of cytochrome P450-substance interactions from biomedical texts.

International journal of pharmaceutics·2025
Same author

Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir.

In vivo (Athens, Greece)·2025

Related Experiment Video

Updated: Feb 13, 2026

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

11.4K

[Dynamic Simulation of Drug-Drug Interactions by Using Multi-level Physiological Modeling & Simulation Platforms].

Fumiyoshi Yamashita1

  • 1Center for Integrative Education of Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|March 6, 2018
PubMed
Summary

Physiologically based pharmacokinetic (PBPK) models predict drug-drug interactions (DDIs) effectively. Open platforms enhance DDI prediction by integrating PBPK and enzyme induction models for systems biology.

Keywords:
drug-drug interactionenzyme inductionmulti-level physiological modeling & simulation platformphysiologically based pharmacokinetics

More Related Videos

Novel 3D/VR Interactive Environment for MD Simulations, Visualization and Analysis
11:29

Novel 3D/VR Interactive Environment for MD Simulations, Visualization and Analysis

Published on: December 18, 2014

12.3K
Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

5.1K

Related Experiment Videos

Last Updated: Feb 13, 2026

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

11.4K
Novel 3D/VR Interactive Environment for MD Simulations, Visualization and Analysis
11:29

Novel 3D/VR Interactive Environment for MD Simulations, Visualization and Analysis

Published on: December 18, 2014

12.3K
Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

5.1K

Area of Science:

  • Pharmacology
  • Systems Biology
  • Computational Biology

Background:

  • Drug-drug interactions (DDIs) mediated by drug-metabolizing enzymes pose significant clinical challenges.
  • Accurate prediction of DDIs is crucial for drug development and clinical practice.
  • Physiologically based pharmacokinetic (PBPK) models are effective for in vitro-in vivo extrapolation of DDIs.

Purpose of the Study:

  • To review open simulation platforms for developing and sharing PBPK models.
  • To evaluate the potential of these platforms for predicting enzyme induction-based DDIs.
  • To explore the integration of PBPK models with dynamic enzyme induction kinetics.

Main Methods:

  • Review of open simulation environments (CellDesigner, PhysioDesigner).
  • Integration of PBPK models for inducers and substrates.
  • Incorporation of dynamic models for enzyme induction kinetics.

Main Results:

  • Open platforms facilitate model development, sharing, and reuse in systems biology.
  • Integration of PBPK and enzyme induction models shows promise for DDI prediction.
  • Open platforms can lead to more generalized and sophisticated PBPK models.

Conclusions:

  • Open platforms offer attractive features for PBPK model development in systems biology.
  • Integrating PBPK and enzyme induction models on open platforms enhances DDI prediction effectiveness.
  • Sharing and reusing models on open platforms promotes scientific advancement in drug interaction studies.